Agios Pharmaceuticals (AGIO) announced its 2026 strategic priorities and key milestones anticipated during the year. Key highlights: AQVESME U.S. commercial launch in thalassemia underway following December 2025 FDA approval; Pre-sNDA meeting with FDA for mitapivat in sickle cell disease anticipated in first quarter of 2026, with planned U.S. regulatory submission to follow; Company progressing early- and mid-stage pipeline in multiple high-value indications; path to profitability through the company’s exi ...